"Reconsidering CYP3A4/5 Genotyping for Ticagrelor Safety: Critical Appraisal of a Narrow Genetic Framework". [PDF]
Clin CardiolClinical Cardiology, Volume 49, Issue 1, January 2026.
Tahir I, Shahbaz H.
europepmc +4 more sources
Is Ticagrelor-Related Dyspnea a Liability or a Biomarker of Response? [PDF]
Clin CardiolClinical Cardiology, Volume 49, Issue 1, January 2026.
Birgün A, Sarıhan A, Kalçık M.
europepmc +2 more sources
CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). [PDF]
Br J Clin PharmacolClopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Dello Russo C +22 more
europepmc +2 more sources
Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal
Periodontology 2000, EarlyView., 2023 Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra +3 more
wiley +1 more source
Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome. [PDF]
Clin CardiolThe CYP3A5 rs776746 CC genotype is a strong biomarker for ticagrelor‐induced dyspnea, conferring a 2.3‐fold higher risk. Genotype‐guided antiplatelet therapy may mitigate this adverse reaction, enabling personalized treatment for ACS patients. ABSTRACT Background Dual antiplatelet therapy with aspirin and a P2Y₁₂ inhibitor is standard for patients with
Zhang Y +5 more
europepmc +2 more sources
Metabolism of ticagrelor in patients with acute coronary syndromes. [PDF]
, 2018 © The Author(s) 2018Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its ...
B Ibanez +41 more
core +2 more sources
More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]
, 2018 © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M +6 more
core +3 more sources
Ticagrelor Removal From Human Blood
JACC: Basic to Translational Science, 2017 Summary: The authors devised an efficient method for ticagrelor removal from blood using sorbent hemadsorption. Ticagrelor removal was measured in 2 sets of in vitro experiments.
George O. Angheloiu, MD +5 more
doaj +1 more source
Systematic review and meta-analysis of optimal P2Y₁₂ blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome [PDF]
, 2016 Background: Patients with diabetes are at increased risk of acute coronary syndromes (ACS) and their mortality and morbidity outcomes are significantly worse following ACS events, independent of other comorbidities.
Brown, Oliver I +2 more
core +1 more source
Fluorescence quenching-based immunological probe for ticagrelor monitoring
Frontiers in Bioengineering and Biotechnology, 2023 Introduction: Ticagrelor is extensively utilized for the treatment of acute coronary syndromes (ACS), but its platelet aggregation inhibitory effects can potentially result in tissue bleeding, posing a serious risk to patients’ lives.Methods: In this ...
Shengshuo Zhang +10 more
doaj +1 more source